ArticleJournal of neuroendovascular therapy2025
Outcomes of Emergent Stenting with Antiplatelet Therapy in Patients with Large Vessel Occlusion Stroke with or without Intravenous Tissue Plasminogen Activator.
Article in Journal of neuroendovascular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the difference in outcomes after emergent stenting with antiplatelet therapy for large vessel occlusion (LVO) stroke in patients with and without prior intravenous tissue plasminogen activator (IV tPA). Methods: Patients who arrived at our hospital within 4.5 h of symptom onset and underwent endovascular therapy (EVT) for LVO between January 2015 and March 2023 were analyzed retrospectively. Patients were included if they underwent stenting for atherosclerotic lesions or arterial dissection with antiplatelet therapy during EVT. The safety and clinical outcomes were compared between patients who received IV tPA before EVT (IV tPA group) and those who did not (no-IV tPA group). The primary outcome was symptomatic intracranial hemorrhage (SICH) within 48 h of EVT. Results: Overall, 54 patients were included in the analysis, with a median age of 72 years (interquartile range [IQR]: 53-74); 41 (76%) were women. The median pre-stroke modified Rankin Scale (mRS) score was 0 (IQR: 0-2), and the median National Institutes of Health Stroke Scale (NIHSS) score was 7 (IQR: 1-21). These patients underwent emergent stenting with antiplatelet therapy during EVT, with stenting performed in the cervical carotid artery and intracranial artery in 38 and 16 patients, respectively. Thirty-one of 54 patients received IV tPA before EVT. Sex, age, NIHSS score on admission, or Alberta Stroke Program Early Computed Tomographic Score on non-contrast CT did not differ significantly between the IV tPA and no-IV tPA groups. Final modified thrombolysis in cerebral infarction scores ≥2b were achieved more frequently in the IV tPA group than in the no-IV tPA group (97% vs. 87%; p = 0.30). SICH (13% vs. 0%; p = 0.13) and any intracranial hemorrhage (ICH) (29% vs. 8.7%; p = 0.09) occurred more frequently in the IV tPA group than in the no-IV tPA group. The rate of achieving mRS scores of 0-2 at 3 months after stroke onset was lower in the IV tPA group [11 (35%) vs. 13 (57%); p = 0.17]. Conclusion: Among patients who received emergent stenting with antiplatelet therapy, successful reperfusion was achieved more frequently in the IV tPA group than in the no-IV tPA group, although the former exhibited a higher SICH rate and worse functional outcomes. These findings suggest that prior IV tPA administration may increase the risk of hemorrhagic complications in cases requiring emergent stenting with antiplatelet therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.